Lilly (Eli) (LLY)
Health Care · Innovative pharmaceuticals
A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss franchises driving exceptional growth.
What Lilly (Eli) does
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across therapeutic areas including cardiometabolic health, oncology, immunology, and other disease areas. The company operates a single business segment focused on innovative medicines, manufacturing through facilities in the U.S., Europe, and Asia, and distributing to approximately 90 countries globally. Its long-term success depends on continuous discovery, acquisition, development, and commercialization of innovative medicines.
Themes: ["GLP-1 / diabetes","Weight loss and obesity","Oncology precision medicine","Cardiometabolic health","Immunology and oncology","Cardiovascular disease prevention","Chronic kidney disease","AI and emerging technologies","Global pharmaceutical commercialization"]
Fundamentals
- Price$1,216.95 as of 2026-07-09 close
- Market cap$1.15T as of 2026-07-10
- 1-year return+54.6% as of 2026-07-09 close
- P/E45.52 as of 2026-07-10
- Net margin+35.0% as of 2026-07-10
- Gross margin+82.8% as of 2026-07-10
- ROE+101.3% as of 2026-07-10
- Debt / equity1.39 as of 2026-07-10
- Revenue growth (YoY)+47.4% as of 2026-07-10
- Revenue CAGR (3y)+31.7% SEC XBRL
- Beta0.50 as of 2026-07-10
Dividend: yield +0.6%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Significant R&D costs and uncertainties in clinical trial timing, regulatory approval processes, and ability to meet trial expectations","Dependence on relatively few products and product classes for majority of revenue; intellectual property expiration risks and biosimilar/generic competition","Pricing pressures from government and private actors, implementation of voluntary U.S. drug pricing agreement, and reimbursement uncertainties"]
Competitors & peers
- Novo Nordisk (NVO)
- Pfizer (PFE)
- Roche (RHHBY)
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- AstraZeneca (AZN)
- Regeneron Pharmaceuticals (REGN)
- Amgen (AMGN)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.